Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration

Retina

Volumn 35, Issue 3, 2015, Pages 454-458

  Enders, Philip ^a   Muether, Philipp S ^a   Hermann, Manuel ^a   Ristau, Tina ^a   Fauser, Sascha ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

age related macular degeneration; plasma; ranibizumab; Vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SUBRETINAL NEOVASCULARIZATION; AGED, 80 AND OVER; BLOOD; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; PROSPECTIVE STUDIES; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84924298713     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000320     Document Type: Article

References (11)

1. Schmucker C, Ehlken C, Agostini HT,. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 2012; 7: e42701.
2. Zehetner C, Kirchmair R, Huber S,. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013; 97: 454-459.
3. Carneiro AM, Costa R, Falcao MS,. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012; 90: e25-e30.
4. Gu X, Yu X, Dai H,. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res 2014; 39: 518-521.
5. Yeung YA, Wu X, Reyes AE,. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010; 70: 3269-3277.
6. Kim H, Robinson SB, Csaky KG,. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009; 15: 2803-2812.
7. Chakravarthy U, Harding SP, Rogers CA,. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382: 1258-1267.
8. Chakravarthy U, Harding SP, Rogers CA,. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411.
9. Grierson R, Meyer-Rüsenberg B, Kunst F,. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration. J Ocul Pharmacol Ther 2013; 29: 530-538.
10. Kodjikian L, Souied EH, Mimoun G,. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013; 120: 2300-2309.
11. Krebs I, Schmetterer L, Boltz A,. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013; 97: 266-271.